Result of AGM

RNS Number : 8678C

Redx Pharma plc

20 April 2017

 

20 April 2017

REDX PHARMA PLC

("Redx" or "the Company")

Result of Annual General Meeting

Redx, the drug discovery and development company, announces that all resolutions at the Group's Annual General Meeting, held today, were duly passed.

For further information, please contact:

Redx Pharma Plc
Neil Murray, Chief Executive	T: [phone]
Karl Hård, Head of Investor Relations & Corporate Communications	T: [phone]
Cantor Fitzgerald Europe (Nomad & Joint Broker)	T: [phone]
Phil Davies / Michael Reynolds

About Redx Pharma Plc

Company website: redxpharma.com

Redx is focused on the discovery and development of proprietary, small molecule therapeutics to address areas of high, unmet medical need, principally in cancer, infection and immunology, providing a pipeline of assets to larger and emerging companies. By improving the characteristics of existing drug classes to create highly differentiated, novel, best-in-class drugs, Redx has already established a broad portfolio of proprietary drug programs.

 

END

 

 

RAGPGURGCUPMGUU